Immunity by Cell Press dedicates the cover of Volume 59, Issue 2,10 February 2026 to our study reporting the preclinical data underpinning the REMaST® therapeutic platform.
Cristiana Vignoli, CEO of Hemera, stated:“The cover of Immunity confirms the value of Italian research in generating global scientific and clinical impact. The published results demonstrate that we are building a new frontier in regenerative medicine capable of radically transforming the way tissue damage is addressed. Our goal is to complete the path toward clinical translation, offering patients a therapeutic opportunity that until now seemed out of reach.”
The study documents rigorous preclinical evidence of the regenerative potential of macrophages, demonstrating neuronal survival, axonal regrowth, and functional recovery in severe spinal cord injury models. These findings help redefine the role of these cells in the context of regenerative medicine and support the development of the REMaST® cell therapy.
For Hemera, this editorial recognition represents a strategic milestone in the international validation process of its proprietary therapeutic platform and strengthens the company’s positioning within the advanced cell therapy landscape, reinforcing its trajectory of industrial value creation.
We are particularly proud of this achievement, which attests to the robustness of Hemera’s science and its commitment to translating this remarkable discovery into tangible therapeutic solutions for patients with unmet clinical needs.